Patents Examined by Ekaterina Poliakova
  • Method of treating cancer by antisense oligonucleotides targeting PRDM15
    Patent number: 11136579
    Abstract: The present invention relates to antisense oligonucleotides for modulating the activity of PRDM15 and use thereof in the treatment of cancer. In particular, said antisense oligonucleotides are capable of inducing the skipping of an exon of a PRDM15 mRNA. The present invention also relates to a method for determining prognosis in a patient with cancer, or selecting a therapeutic strategy for a patient with cancer, by assessing the level of PRDM15 nucleic acid, protein or activity in a sample.
    Type: Grant
    Filed: September 4, 2017
    Date of Patent: October 5, 2021
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Ernesto Guccione, Keng Boon Dave Wee
  • Splice-switching oligonucleotides and methods of use
    Patent number: 11136584
    Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR or EGFR expression and methods of using these splice-switching oligonucleotides to treat cancer.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: October 5, 2021
    Assignee: Duke University
    Inventors: Jennifer Freedman, Brendon Patierno, Bonnie Lacroix, Timothy Robinson, Bruce Sullenger, Daniel George, Steven Patierno
  • Methods for modulating splicing
    Patent number: 11129829
    Abstract: Described herein are methods of use of small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: September 28, 2021
    Assignee: SKYHAWK THERAPEUTICS, INC.
    Inventors: Michael Luzzio, Kathleen McCarthy, Botao Liu
  • Medicament for the treatment of acute liver failure
    Patent number: 11123358
    Abstract: The present invention relates to a compound for use as a medicament in the treatment or prevention of acute liver failure, which acute liver failure is induced by intoxication prior to or following administration of the compound. Accordingly, the invention relates to the compound for use in the treatment of an intoxication that without treatment is expected to result in acute liver failure or that without treatment is sufficient to induce acute liver failure. The invention also provides the compound for use in the treatment, and a corresponding method for the treatment of an intoxication sufficient to induce acute liver failure.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: September 21, 2021
    Assignee: Medizinische Hochschule Hannover
    Inventors: Amar Sharma, Michael Ott, Tobias Cantz, Dakai Yang
  • Methods for treating subjects suffering from acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles
    Patent number: 11097014
    Abstract: A nanoparticle delivery system designed for sustained delivery of microRNA-150 (miR-150) to FLT3-overexpressing acute myeloid leukemia (AML) cells, the delivery system comprising poly(amidoamine) (PAMAM) dendrimers complexed with miR-150, wherein at least one dendrimer is surface-functionalized with a ligand specific for FLT3 receptor, and methods for treating AML characterized by FLT3-overexpression are provided.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: August 24, 2021
    Assignees: University of Cincinnati, Board of Trustees of the University of Illinois, University of Chicago
    Inventors: Jianjun Chen, Seungpyo Hong, Xi Jiang, Zejuan Li
  • Methods and compositions for treating a Serpinc1-associated disorder
    Patent number: 11091759
    Abstract: The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and to treat subjects having a Serpinc1-associated disease, e.g., a bleeding disorder, such as a hemophilia.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: August 17, 2021
    Assignee: Genzyme Corporation
    Inventors: Akin Akinc, Benny Sorensen, Pushkal Garg, Gabriel Robbie
  • Therapeutic oligonucleotides
    Patent number: 11091765
    Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a therapeutic target such as Complement Component 1, Q Subcomponent (C1q) or a subunit thereof.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: August 17, 2021
    Assignee: Caris Science, Inc.
    Inventors: Heather O'Neill, Mark Miglarese, David Spetzler
  • Functional tRNA-aptamer molecules
    Patent number: 11085045
    Abstract: The present invention provides functional aptamer-comprising tRNA molecules, useful in the study of tRNA and ribosomal activity.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: August 10, 2021
    Assignees: Anima Biotech Inc., Thomas Jefferson University
    Inventors: Iris Alroy, Ya-Ming Hou, Howard Gamper
  • Methods of treating transthyretin (TTR) mediated amyloidosis
    Patent number: 11079379
    Abstract: Disclosed herein are methods for reducing or arresting an increase in a Neuropathy Impairment Score (NIS) or a modified NIS (mNIS+7) in a human subject by administering an effective amount of a transthyretin (TTR)-inhibiting composition.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: August 3, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventor: Brian Bettencourt
  • Antisense oligonucleotides
    Patent number: 11072795
    Abstract: The present invention relates to antisense oligonucleotides for modulating the activity of glycine decarboxylase (GLDC). In particular, the present invention relates to antisense oligonucleotides capable of inducing exon skipping of RNA. Also claimed are pharmaceutical compositions, kits and methods of treating cancer and inducing exon-skipping using said antisense oligonucleotides. In addition, a method for aiding the categorising or determining prognosis of a cancer or in selecting a therapeutic strategy for a patient with cancer, based on assessing the level of GLDC nucleic acid, protein or activity in a sample derived from the patient is provided.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: July 27, 2021
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Uttam Surana, Dave Keng Boon Wee, Jing Lin, Bing Lim
  • Polycomb-associated non-coding RNAs
    Patent number: 11066673
    Abstract: This invention relates to long non-coding RNAs (lncRNAs), libraries of those lncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting lncRNAs.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: July 20, 2021
    Assignee: The General Hospital Corporation
    Inventors: Jeannie T. Lee, Jing Zhao, Kavitha Sarma, Mark Borowsky, Toshiro Kendrick Ohsumi
  • Methods and compositions for the specific inhibition of transthyretin (TTR) by double stranded RNA
    Patent number: 11066672
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing transth:yretin (TTR) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: July 20, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • RNA interference of galectin-3 expression and methods of use thereof
    Patent number: 11058708
    Abstract: Galectin-3 is a pro-inflammatory molecule functioning as a cytokine hub, and also regulates unfolded protein responses (UPR) and ER stress. Thus, galectin-3 serves as a target for ameliorating inflammatory diseases such as allergic inflammation and diabetic inflammation and insulin resistance. RNA interference of endogenous galectin-3 expression, upregulates IL-12, IL-10 while downregulating IL-23 production, which offers protection against allergic inflammation. In addition, endogenous galectin-3 knockdown causes upregulation of XBP1, alleviating ER stress. Together, upregulated XBP1 and IL-10 offer protection against obesity-induced inflammation. Therefore, the embodiment of the invention resides in RNA interference of endogenous galectin-3 in appropriate cell types in order to rectify allergic and/or diabetic inflammation.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: July 13, 2021
    Inventor: Swey-Shen Chen
  • Method of treatment
    Patent number: 11046956
    Abstract: The present disclosure teaches the treatment of a blood pathology, such as a blood pathology associated with impaired hemoglobin synthesis including the treatment of ?-thalassemia or a related hemoglobinopathy.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: June 29, 2021
    Assignee: Hudson Institute of Medical Research
    Inventor: Jim Vadolas
  • P-ethoxy nucleic acids for STAT3 inhibition
    Patent number: 11041153
    Abstract: Provided herein are improved delivery systems for oligonucleotides, said delivery system comprising a liposome that comprises neutral phospholipids and a P-ethoxy oligonucleotide, which targets a STAT3-encoding polynucleotide. Methods of treating patients with said delivery systems are also provided.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: June 22, 2021
    Assignee: BIO-PATH HOLDINGS, INC.
    Inventor: Ana Tari Ashizawa
  • siRNA compositions that specifically down regulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease
    Patent number: 11028393
    Abstract: The invention provides siRNA compositions that specifically downregulates expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD).
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: June 8, 2021
    Assignee: Purdue Research Foundation
    Inventors: Wanqing Liu, Yoon Yeo
  • TNF-alpha-binding aptamer, and therapeutic use for same
    Patent number: 11028395
    Abstract: The present invention relates to a TNF-?-binding RNA aptamer disclosed in SEQ ID NO: 1 or SEQ ID NO: 2, and to the therapeutic use thereof.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: June 8, 2021
    Assignee: BIOIS CO., LTD.
    Inventor: Sung-Chun Kim
  • Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing
    Patent number: 11028391
    Abstract: Methods and compositions are provided for inhibiting or treating metastasis based on discoveries regarding Kif19 and Cep192. Methods and compositions are provided for enhancing wound healing, treating fibrosis, reducing scarring and treating nerve pain.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: June 8, 2021
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: David Sharp, Brian O'Rourke
  • Angiotensinogen (AGT) iRNA compositions and methods of use thereof
    Patent number: 11015201
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the AGT gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an AGT gene and to methods of preventing and treating an AGT-associated disorder, e.g., high blood pressure.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: May 25, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Donald Foster, Gregory Hinkle, Mark K. Schlegel
  • MicroRNA 19a/19b for use in treating a pathological condition associated with bone loss or reduced muscle function
    Patent number: 11013755
    Abstract: The invention relates to inhibitors of microRNAs 19a and 19b and their use for treating or preventing conditions or diseases which are associated with bone loss, in particular osteoporosis and osteogenesis imperfect (01). The inhibitors are also useful for inducing an anabolic effect in bone, either alone or when administered in combination with parathyroid hormone or a recombinant fragment thereof. The invention further relates to inhibitors of microRNAs 19a and 19b and their use for treating or preventing conditions or diseases which are associated with reduced muscle function, in particular muscle degeneration and muscle atrophy. The inhibitors are also useful for stabilizing and/or strengthening muscle function. In addition, inhibitors of microRNAs 19a and 19b can be used for treating or preventing cancer-related bone destruction or bone metastasis.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: May 25, 2021
    Assignee: UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF
    Inventors: Eric Hesse, Hanna Taipaleenmäki, Hiroaki Saito